Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9957824 | 0.81 | PDE4D (0.47) | ALDH1A1RAB9AKDM4EPKM | |
| SCHEMBL3574484 | 0.79 | L3MBTL1 (0.46) | ALDH1A1ABCC1RAB9AL3MBTL1BUB1 | |
| SCHEMBL3584391 | 0.74 | ALDH1A1 (0.37) | ALDH1A1ABCC1L3MBTL1HCAR3KDM4E | |
| SCHEMBL5017568 | 0.73 | ABCC1 (0.56) | ALDH1A1ABCC1RAB9AL3MBTL1KDM4E | |
| SCHEMBL21707913 | 0.72 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1KDM4EPKM | |
| SCHEMBL8306201 | 0.72 | L3MBTL1 (0.42) | ALDH1A1ABCC1L3MBTL1KDM4EPKM | |
| SCHEMBL14710261 | 0.72 | L3MBTL1 (0.36) | ALDH1A1ABCC1RAB9AL3MBTL1KDM4E | |
| SCHEMBL8307577 | 0.71 | ALDH1A1 (0.39) | ALDH1A1RAB9AL3MBTL1KDM4EPKM | |
| SCHEMBL7240027 | 0.69 | LMNA (0.34) | — | |
| SCHEMBL8706277 | 0.69 | ALDH1A1 (0.55) | ALDH1A1RAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | claimed |
| EP-1984340-B1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-06-27 | — | — | EP | disclosed |
| CN-101379036-B | Anthranilamide/2-amino-heteroarene carboxamide derivatives | HOFFMANN LA ROCHE | 2011-06-01 | — | — | CN | disclosed |
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| CN-101379036-A | Anthranilamide/2-amino-heteroarene carboxamide derivatives | HOFFMANN LA ROCHE (CH) | 2009-03-04 | — | — | CN | disclosed |
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | AADAT, AAAS, AADAC | ALDH1A1 1414/4885TTK 3710/4885ABCC1 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.